Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Trobalt 50 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Purple, round, film-coated tablets of 5.6 mm, marked with “RTG 50” on one side. |
Each film-coated tablet contains 50 mg of retigabine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Retigabine |
In vitro studies indicate that retigabine acts primarily through opening neuronal potassium channels. This stabilises the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of epileptiform action potential bursts. The mechanism of action of retigabine on potassium channels has been well documented, however other mechanisms by which retigabine may assert an antiepileptic effect have yet to be fully elucidated. |
| List of Excipients |
|---|
|
Tablet core: Croscarmellose sodium Film-coating: 50 mg tablets: Polyvinyl alcohol |
50 mg tablets:
Opaque PVC-PVDC-aluminium foil blisters. Packs containing 21or 84 film-coated tablets.
Not all pack sizes may be marketed.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
EU/1/11/681/001, EU/1/11/681/002
Date of first authorisation: 28 March 2011
Date of latest renewal: 14 January 2016
| Drug | Countries | |
|---|---|---|
| TROBALT | Estonia, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
